Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
Overview of electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company that specializes in non-invasive vagus nerve stimulation (nVNS) therapies. As an innovator in vagus nerve stimulation and neuromodulation, the company develops solutions for a wide range of conditions in neurology, psychiatry, and gastroenterology, in addition to general wellness applications. Its core technology platform is designed to improve patient care while promoting overall human performance.
Core Business and Product Offerings
The company’s product portfolio is built around its proprietary nVNS technology. Its flagship product, which has secured FDA clearance for the adjunctive treatment of cluster headaches and migraines, exemplifies its commitment to addressing debilitating neurological conditions. By delivering a controlled electrical impulse to the vagus nerve, these devices assist in modulating neural pathways, which may lead to improved clinical outcomes for conditions such as epilepsy, gastric motility disorders, depression, and anxiety.
Additionally, electroCore has extended its technology into products like TAC-STIM, a cutting-edge tool originally developed in collaboration with military research organizations. TAC-STIM is designed for non-invasive stimulation to enhance cognitive performance, improve focus, and accelerate learning in high-pressure operational environments. This diversification into consumer wellness products and performance enhancement applications underscores the company’s strategic approach to leveraging its core technology across multiple domains.
Innovation and Technology
electroCore employs advanced bioelectronic techniques as part of its comprehensive nVNS technology platform. Its products are characterized by precise stimulation parameters, enabling patient-administered therapies that are both effective and safe. The company continuously invests in research and clinical trials to validate the efficacy of its device applications, whether in therapeutic settings for primary headaches or in enhancing human performance for military training scenarios. By integrating rigorous scientific methods with innovative engineering, electroCore maintains a robust pipeline that appeals to both healthcare professionals and consumers seeking non-pharmaceutical solutions.
Global Presence and Market Position
With its headquarters in the United States and operational offices in key international markets such as Germany, the United Kingdom, Italy, Australia, and Canada, electroCore has established a global footprint. This geographic diversity not only enhances its market reach but also enriches its research collaborations across continents. The company is well-positioned within the bioelectronic medicine industry and competes with firms focused on non-invasive neuromodulation. Its strategic emphasis on safety, efficacy, and ease-of-use has helped carve out a distinct niche among healthcare providers, institutions, and direct-to-consumer channels.
Research, Clinical Evidence, and Collaborations
Robust clinical research forms the backbone of electroCore's operations. Numerous studies have demonstrated the potential benefits of nVNS in accelerating sensorimotor learning, enhancing cognitive performance, and managing pain symptoms. Collaborative research with organizations such as the Air Force Research Laboratory and leading clinical centers reinforces the credibility of its technology and builds trust in its applications. By continually updating its clinical evidence base, the company provides health professionals and investors with objective, data-driven insights into its products' performance.
Business Strategy and Market Impact
The company generates revenue from multiple channels, including direct sales, strategic partnerships, and wholesale distribution. Its business model capitalizes on the growing demand for non-invasive therapeutic alternatives in both the medical and consumer wellness sectors. While navigating challenges such as regulatory compliance and competitive market dynamics, electroCore emphasizes technological differentiation and clinical validation to secure its market position.
Through its unique combination of advanced technology, global distribution, and continuous clinical research, electroCore represents a compelling integration of medical innovation and practical consumer applications. Its clear focus on improving quality of life through non-pharmaceutical interventions has resonated with healthcare providers and patients alike, making it a notable entity within the neuromodulation space.
Conclusion
electroCore, Inc. exemplifies a successful blend of advanced engineering and clinical expertise in the realm of bioelectronic medicine. Its diverse product offerings, international presence, and commitment to rigorous scientific standards position the company as a distinguished player in non-invasive vagus nerve stimulation. By maintaining a balance between technological innovation and clinical validation, electroCore continues to contribute meaningfully to modern neuromodulation and wellness, providing valuable insights for investors and industry observers seeking an in-depth understanding of its business model.
electroCore (ECOR) reported record financial results for full year 2024, achieving net sales of $25.2 million, a 57% increase from $16.0 million in 2023. The growth was primarily driven by an 85% increase in Rx gammaCore sales through VA/DOD channels and a 174% rise in Truvaga sales.
The company's net loss decreased by 37% to $11.9 million in 2024, with gross profit reaching $21.4 million at an 85% margin. Operating expenses totaled $33.6 million, including $2.4 million in R&D and $31.2 million in SG&A costs. Cash burn improved significantly, with net cash used in operations decreasing 53% to $7.0 million.
The company ended 2024 with $12.2 million in cash and equivalents, up from $10.6 million at the end of 2023. The adjusted EBITDA net loss improved to $9.0 million from $15.4 million in the previous year.
electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has scheduled its fourth quarter and full year 2024 financial results announcement for Wednesday, March 12, 2025, after market close. The company will host a webcast and conference call at 5:30 PM EDT where management will discuss the financial results and conduct a Q&A session.
electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has announced its participation in two major investor conferences in March 2025.
The company will attend the 37th Annual Roth Conference from March 16-18 at the Laguna Cliffs Marriott Resort & Spa in Dana Point, California, where Chief Financial Officer Joshua Lev will host one-on-one meetings with investors.
Additionally, electroCore will participate in LSI USA '25 from March 17-21 at the Waldorf Astoria Monarch Beach Resort in Dana Point, California, where CFO Joshua Lev will manage the company's exhibition presence.
Interested investors can schedule meetings through their Roth or LSI representatives or by contacting FNK IR at ecor@fnkir.com.
electroCore (NASDAQ: ECOR) has announced a distribution agreement with Spark Biomedical Inc. to distribute Sparrow Ascent™ within certain Department of Veterans Affairs (VA) facilities. Sparrow Ascent is an FDA-cleared non-invasive transcutaneous auricular neuromodulation device prescribed for treating opioid withdrawal symptoms.
The partnership aims to leverage electroCore's established distribution network to expand access to this drug-free, wearable neurostimulation solution for veterans. The Sparrow Ascent therapy complements electroCore's existing gammaCore™ therapy portfolio, offering VA customers a non-addictive treatment option for opioid withdrawal symptoms.
electroCore (NASDAQ: ECOR) has announced the availability of its flagship wellness product, Truvaga Plus, on Amazon's retail platform. The hand-held vagus nerve stimulator is designed to provide stress relief, improve sleep, enhance peace of mind, and improve focus through gentle vagus nerve activation.
CEO Dan Goldberger highlighted that the Amazon listing will help showcase their product to a broader audience through America's largest e-commerce marketplace, potentially increasing consumer accessibility and adoption.
electroCore (Nasdaq: ECOR) has strengthened its intellectual property portfolio with two new U.S. patents granted by the USPTO. The first patent (No. 12,208,263), issued on January 28, 2025, covers methods for vagal nerve stimulation using electrodes with conductive gel on the neck, including position adjustment based on pressure sensation.
The second patent (No. 12,213,795), issued on February 4, 2025, relates to systems and methods for nerve modulation that incorporate data storage of electrical impulse parameters and patient monitoring, including the ability to track user status data such as headache severity.
electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has announced its participation in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. The event is scheduled for February 11-12, 2025 in Snowbird, Utah.
CEO Dan Goldberger will be available for one-on-one meetings throughout the conference. Interested investors can arrange meetings through their BTIG representative or by contacting electroCore's investor relations team directly at investors@electrocore.com.
electroCore (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced the issuance of five new U.S. patents by the USPTO between December 17, 2024, and December 31, 2024.
These patents include:
- US Patent No. 12,168,128 - Issued on December 17, 2024, it covers systems and methods for treating medical conditions by transmitting electrical impulses to the trigeminal nerve, controlled via a mobile device.
- US Patent No. 12,168,121 - Also issued on December 17, 2024, it relates to treating developmental disorders in fetuses by delivering electrical impulses to a nerve in pregnant women.
- US Patent No. 12,172,015 - Issued on December 24, 2024, it involves a medical device generating electrical impulses and using a smart card for refilling the device after specific usage.
- US Patent No. 12,172,016 - Issued on December 24, 2024, it pertains to non-invasive vagal nerve stimulation for treating Parkinson's disease.
- US Patent No. 12,179,012 - Issued on December 31, 2024, it describes a device for non-invasive nerve stimulation, transmitting electrical impulses through the skin to a target nerve.
These patents enhance electroCore's intellectual property portfolio, potentially strengthening its market position in bioelectronic medicine.
electroCore (ECOR) has announced a definitive agreement to acquire NeuroMetrix (NURO), focusing on its Quell platform while excluding the DPNCheck business. The acquisition aims to strengthen electroCore's position in the bioelectronic health and wellness sector. Quell is a wearable neuromodulation platform FDA-authorized for fibromyalgia symptoms and lower-extremity chronic pain treatment.
The transaction value will equal NURO's net cash balance at closing, with NURO shareholders receiving non-tradeable contingent value rights (CVRs). Each CVR includes rights to DPNCheck divestiture proceeds and up to $500,000 in Quell product royalties over two years post-closing. The deal is expected to close by Q1 2025, subject to NURO shareholder approval.
NeuroMetrix reported Q3 2024 results with total revenue of $600,000, including Quell revenue of $184,000 (50% YoY increase), and a net loss of $1.5 million.
electroCore (Nasdaq: ECOR) announces that its wellness product Truvaga Plus has received recognition in the first-ever Woman's World Magazine 50 over 50 Award. The award evaluation criteria included quality, effectiveness, and value, specifically targeting products beneficial for women over 50. The product is designed to help reduce stress, enhance sleep quality, and improve mental focus. CEO Dan Goldberger expressed pride in this recognition, emphasizing the company's commitment to developing solutions that enhance quality of life.
FAQ
What is the current stock price of Electrocore (ECOR)?
What is the market cap of Electrocore (ECOR)?
What is the primary focus of electroCore, Inc.?
How does electroCore generate revenue?
What conditions are targeted by electroCore's therapies?
How is electroCore positioned within the neuromodulation market?
What is TAC-STIM and who benefits from its use?
What sets electroCore's technology apart from competitors?
